Roche seeks Kadcyla boost to fend off Herceptin biosimilarsAs biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer Share XRoche seeks Kadcyla boost to fend off Herceptin biosimilarshttps://pharmaphorum.com/news/roche-seeks-new-kadcyla-indication/
FDA approves Samsung/Merck & Co’s Herceptin biosimilarThe FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck Share XFDA approves Samsung/Merck & Co’s Herceptin biosimilarhttps://pharmaphorum.com/news/fda-approves-samsung-merck-cos-herceptin-biosimilar/
Lilly’s Verzenios approved by NICENICE has published draft guidance that now recommends Eli Lilly’s breast cancer drug Verzenios for use on the Share XLilly’s Verzenios approved by NICEhttps://pharmaphorum.com/news/lillys-verzenios-approved-nice/
Liquid biopsy-based system could prevent cancer from spreadingAngle’s liquid biopsy system has been used in new cancer research that could provide a novel way to Share XLiquid biopsy-based system could prevent cancer from spreadinghttps://pharmaphorum.com/news/liquid-biopsy-based-system-could-prevent-cancer-from-spreading/
Breast cancer chatbot to launch in USA chatbot helping patients with breast cancer is to hit the key US market after attracting in 10,000 Share XBreast cancer chatbot to launch in UShttps://pharmaphorum.com/news/breast-cancer-chatbot-to-launch-in-us/
Roche’s Tecentriq gets fast review in triple negative breast cancerThe FDA has granted a fast review for Roche/Genentech’s Tecentriq in combination with Celgene’s Abraxane for certain patients Share XRoche’s Tecentriq gets fast review in triple negative breast cancerhttps://pharmaphorum.com/news/roches-tecentriq-gets-fast-review-in-triple-negative-breast-cancer/
Roche’s Tecentriq posts trial wins in two key indicationsRoche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple Share XRoche’s Tecentriq posts trial wins in two key indicationshttps://pharmaphorum.com/news/roches-tecentriq-posts-trial-wins-in-two-key-indications/
Novartis wants to blaze a trail in breast cancer with PI3K drugNovartis is preparing to file its PI3K drug combination for a certain group of breast cancer patients, after Share XNovartis wants to blaze a trail in breast cancer with PI3K drughttps://pharmaphorum.com/news/novartis-wants-to-blaze-a-trail-in-breast-cancer-with-pik3-drug/
Pfizer’s Talzenna PARP breast cancer drug approved in USThe US drug regulator has approved Pfizer’s breast cancer medicine Talzenna (talazoparib) for patients with a certain mutation. Share XPfizer’s Talzenna PARP breast cancer drug approved in UShttps://pharmaphorum.com/news/pfizers-talzenna-parp-breast-cancer-drug-approved-in-us/
